We are a late-stage company developing fusion protein medicines. Our fusion protein approach tethers a tumor-targeting antibody fragment to a protein cytotoxic payload to form a single protein molecule designed to selectively and broadly kill cancer cells while minimizing toxicity to healthy cells and to activate the body’s innate immune response system.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.